Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

NCT07283822 is registered in ClinicalTrials.gov with Seda S. Tolu as lead sponsor.

NCT NCT07283822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07283822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas
Lead sponsor
Seda S. Tolu
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2025
Completion date
January 31, 2029
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphomas, gray zone lymphoma, hodgkin disease lymphoma, hodgkin disease recurrent, non-hodgkin lymphoma, non-hodgkin lymphoma refractory/ relapsed, peripheral t-cell lymphoma, primary mediastinal b cell lymphoma